

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

TPC-1

RRID:CVCL_6298

Type: Cell Line

Proper Citation

RRID:CVCL_6298

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6298

Proper Citation: RRID:CVCL_6298

Description: Cell line TPC-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Thyroid gland papillary carcinoma

Defining Citation: [PMID:2334411](#), [PMID:2516841](#), [PMID:2823470](#), [PMID:7491517](#), [PMID:11439348](#), [PMID:14522906](#), [PMID:15980887](#), [PMID:16778181](#), [PMID:17725429](#), [PMID:17804723](#), [PMID:18713817](#), [PMID:19087340](#), [PMID:21868764](#), [PMID:22087789](#), [PMID:23162534](#), [PMID:23833040](#), [PMID:30737244](#), [PMID:36599897](#)

Comments: Population: Japanese.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TPC-1

Synonyms: TPC1

Cross References: BTO:BTO_0006508, EFO:EFO_0022629, BCRJ:0397, ChEMBL-Cells:ChEMBL3308064, ChEMBL-Targets:ChEMBL613836, CLS:305054, Cosmic:686571, Cosmic:686572, Cosmic:686728, Cosmic:849969, Cosmic:931238, Cosmic:1021385, Cosmic:1084277, Cosmic:1132593, Cosmic:1152124, Cosmic:1237448, Cosmic:1239954, Cosmic:1280041, Cosmic:2036695, Cosmic:2054096, Cosmic:2319845, Cosmic:2613255, IARC_TP53:25009, Millipore:SCC147, PubChem_Cell_line:CVCL_6298, TOKU-E:4065, Wikidata:Q54972844

ID: CVCL_6298

Record Creation Time: 20220427T221632+0000

Record Last Update: 20260830T000127+0000

Ratings and Alerts

No rating or validation information has been found for TPC-1.

No alerts have been found for TPC-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 394 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Arawker MH, et al. (2026) STAT1-TCTN3 axis drives papillary thyroid carcinoma progression by accelerating the cell cycle and promoting tumor cell migration and invasion. International journal of biological macromolecules, 344(Pt 1), 150436.

Son J, et al. (2026) Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells. Molecular oncology, 20(4), 1041.

Ablinger C, et al. (2026) Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer. International journal of cancer.

Feng N, et al. (2026) Unveiling ER-Phagy Receptors in Thyroid Cancer: A Combined Approach of Public Data Mining and In Vitro Validation. Clinical Medicine Insights. Oncology, 20, 11795549261460315.

Lv C, et al. (2026) circPTPRM can encode a functional polypeptide circPTPRM-187aa to promote papillary thyroid carcinoma progression. Molecular and cellular endocrinology, 614, 112734.

Bó IFD, et al. (2026) Bisphenol A Induces DNA Damage and Differential Cytotoxicity in Thyroid Cells: High-Dose Effects Challenge Regulatory Thresholds. Journal of applied toxicology : JAT.

Cui T, et al. (2026) PDE4C stabilized by ELAVL1 promotes lymph node metastasis in papillary thyroid cancer. American journal of cancer research, 16(2), 639.

Cirello V, et al. (2025) TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer. The Journal of clinical endocrinology and metabolism.

Iglesias-Hernandez P, et al. (2025) Impact of nanoplastics on thyroid function: Unraveling cellular biokinetics, molecular mechanisms and human risk assessment. *Journal of hazardous materials*, 498, 139890.

Dasgupta U, et al. (2025) Cu₃N-Fe nanocube-based electrochemical sensing of cancer metabolites with minute-scale response time. *Materials horizons*.

Xu FZ, et al. (2025) Pharmacodynamics of huaier aqueous extract against papillary thyroid carcinoma in vivo and in vitro. *Integrative cancer therapies*, 24, 15347354251339073.

Li R, et al. (2025) P4HA2 promotes the progression of papillary thyroid cancer by enhancing degradation of I β B γ to activate NF- κ B signaling pathway. *Cancer cell international*, 25(1), 249.

Wang F, et al. (2025) TSH Ligand-Based CAR-T Cell Effectively Eradicates TSHR-Positive Thyroid Cancer with Favorable Safety Profile. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e13243.

Ruan X, et al. (2025) Enhancer hijacking drives FAM20C expression to promote papillary thyroid cancer progression. *Cancer gene therapy*, 32(8), 854.

Yang Z, et al. (2025) Hypoxia inducible factor-1 α drives cancer resistance to cuproptosis. *Cancer cell*, 43(5), 937.

Lim G, et al. (2025) AURKB and PI3K/AKT/mTOR pathways converge to regulate TERT expression. *iScience*, 28(8), 113194.

Xiao G, et al. (2025) Single-cell RNA-sequencing and spatial transcriptomic analysis reveal a distinct population of APOE- cells yielding pathological lymph node metastasis in papillary thyroid cancer. *Clinical and translational medicine*, 15(1), e70172.

Hsu YC, et al. (2025) Overexpression of NR1D1 Portends Disease Recurrence in Thyroid Cancer. *The Journal of clinical endocrinology and metabolism*, 110(4), 991.

Changoer P, et al. (2025) Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer. *Cancer immunology, immunotherapy : CII*, 75(1), 14.

Poyil PK, et al. (2024) PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects. *Molecular oncology*, 18(3), 691.